Since the 2018 Farm Bill legalized hemp containing less than 0.3% delta-9 THC, the United States has seen an explosion of hemp-derived cannabinoid products, including delta-8 THC, delta-10 THC, and other intoxicating compounds now widely sold online and in everyday retail stores [1]. While state-licensed cannabis products must undergo laboratory testing, potency verification, contaminant screening, and tracking before reaching consumers, many hemp-derived products are sold in a regulatory gray area with limited federal oversight. The U.S. Food and Drug Administration (FDA) has warned that delta-8 THC products have not been evaluated or approved for safe use and may carry risks related to manufacturing practices and contamination [2]. As a result, product safety in the unregulated marketplace has become a growing concern for consumers, regulators, and public health officials alike.
What “Unregulated” Means in Today’s Market
In states where cannabis is legal, regulated products are sold through licensed dispensaries that must comply with strict rules. These programs typically require third-party lab testing for potency, pesticides, heavy metals, microbial contamination, and residual solvents. Products are tracked from seed to sale and must meet labeling and packaging requirements designed to inform and protect consumers.
Hemp-derived products operate differently. Because the 2018 Farm Bill legalized hemp federally, manufacturers began producing cannabinoids such as delta-8 THC and delta-10 THC, often by chemically converting CBD extracted from hemp [1]. These products are frequently sold in smoke shops, gas stations, online marketplaces, and through social media, often outside the strict regulatory systems governing state-legal cannabis. The FDA has cautioned that many delta-8 products have not been evaluated for safety and may be marketed in ways that put public health at risk [2]. This creates confusion, as consumers may assume all cannabis-related products are subject to the same standards when they are not.
Learn More: What Is Delta-8 THC?
Key Safety Risks in the Unregulated Market
The most significant risk in the unregulated cannabis and hemp market is the lack of mandatory third-party testing. In licensed cannabis programs, products are screened before sale to ensure accurate potency and to detect contaminants. Many hemp-derived products sold online or in convenience stores, however, are not held to uniform testing requirements.
According to the FDA, delta-8 THC products have not been evaluated for safe use and may pose risks due to inaccurate labeling and contamination during manufacturing [2]. Misstated THC levels can lead to overconsumption—particularly with edibles, where delayed effects may cause consumers to take more than intended. Inconsistent labeling can also confuse new or inexperienced users who may not understand the differences between various cannabinoids.
Contamination is another serious concern. State cannabis testing programs typically screen for pesticides, heavy metals, residual solvents, and microbial impurities. Products manufactured outside regulated systems may not undergo these checks. The Centers for Disease Control and Prevention (CDC) documented serious lung injuries during the EVALI outbreak linked to certain vaping products, highlighting the risks associated with additives and unregulated ingredients [3]. Combined with youth-appealing packaging and weak age verification in some retail settings, these safety gaps underscore ongoing risks in the unregulated marketplace.
What Trusted Sources and Research Reveal
Federal and state agencies continue to raise concerns about unregulated cannabinoid products. The FDA has reported adverse events associated with delta-8 THC and warned that some products may contain harmful byproducts created during chemical conversion processes [2]. The CDC’s investigation into vaping-related lung injuries further demonstrated the dangers of inhaling unregulated substances [3].
Even in regulated markets, state agencies issue product recalls for contamination or inaccurate potency labeling. The Cannabis Regulators Association (CANNRA) tracks such recalls, illustrating how common safety failures can be—even under structured oversight [4]. Independent laboratory testing has also found some hemp-derived products to be mislabeled or contaminated, reinforcing concerns about inconsistent quality control in unregulated channels.
Why Hemp-Derived Products Are Especially Vulnerable
Hemp-derived intoxicating cannabinoids are particularly vulnerable to safety issues because many are not extracted directly from the plant in meaningful concentrations. Instead, compounds like delta-8 THC are often chemically synthesized from CBD using solvents, acids, and other reagents. If these processes are not carefully controlled and purified, residual chemicals or unintended byproducts may remain in the final product.
The FDA has emphasized that it has not established comprehensive regulatory frameworks for many hemp-derived cannabinoids, resulting in limited oversight and inconsistent manufacturing standards [5]. Unlike state-regulated cannabis programs with mandatory testing and compliance requirements, much of the hemp-derived market relies on voluntary quality control. Without uniform federal standards, safety often depends on the integrity of individual manufacturers.
How Consumers Can Protect Themselves
While the regulatory landscape remains complex, consumers can take practical steps to reduce risk. When possible, purchase cannabis products from state-licensed dispensaries where lab testing, tracking, and labeling standards are required. Most states provide online databases where consumers can verify whether a dispensary is properly licensed.
Reviewing a product’s Certificate of Analysis (COA) is another important safeguard. A COA confirms cannabinoid potency and screens for contaminants such as pesticides, heavy metals, residual solvents, and microbial impurities. This is especially important for hemp-derived products, as the FDA has warned that many delta-8 items have not been evaluated for safety [2].
Consumers should also watch for red flags. Products without batch numbers, QR codes, or accessible lab results lack transparency. Unrealistically high potency claims or prices far below regulated market averages may indicate poor quality control. Asking questions about testing standards, cannabinoid sourcing, and manufacturing practices can help ensure informed decisions. Public health agencies, including the FDA and CDC, have both highlighted risks tied to unregulated cannabinoid and vaping products, reinforcing the value of cautious purchasing [2][3].
The Broader Public Health Impact
The rapid growth of unregulated hemp-derived products has blurred the line between regulated cannabis and loosely controlled alternatives. The FDA has warned that some delta-8 products are marketed in misleading ways, including packaging that resembles CBD or candy, increasing the risk of accidental exposure [2]. Inconsistent potency labeling and unclear dosing guidance raise the likelihood of overconsumption, particularly among new users.
Public health experts and policymakers have expressed concern that safety incidents linked to unregulated products could undermine consumer trust and complicate legalization efforts. The National Conference of State Legislatures (NCSL) notes that states are actively grappling with how to regulate delta-8 and similar cannabinoids, highlighting the ongoing policy challenges created by this evolving marketplace [6].
Conclusion
As the U.S. cannabis and hemp market continues to expand, consumers must navigate a system where not all products are created—or regulated—equally. Federal agencies like the FDA have made clear that many hemp-derived cannabinoids, including delta-8 THC, have not been evaluated for safe use and may carry risks related to contamination and inconsistent potency [2]. While regulated markets are not perfect, they provide structured safeguards that help reduce harm. In today’s crowded and confusing marketplace, prioritizing licensed retailers, verified lab testing, and transparent sourcing over convenience or price remains one of the most effective ways to protect your health.
References
- [1] 2018 Agriculture Improvement Act (Farm Bill), U.S. Congress. https://www.congress.gov/bill/115th-congress/house-bill/2
- [2] U.S. Food and Drug Administration. “5 Things to Know about Delta-8 Tetrahydrocannabinol (Delta-8 THC).” https://www.fda.gov/consumers/consumer-updates/5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc
- [3] Centers for Disease Control and Prevention. “Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products (EVALI).” https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html
- [4] Cannabis Regulators Association (CANNRA). “Cannabis Product Recalls and Safety Alerts.” https://cann-ra.org/resources/product-recalls/
- [5] U.S. Food and Drug Administration. “FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD).” https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
- [6] National Conference of State Legislatures (NCSL). “State Regulation of Delta-8 THC and Other Hemp-Derived Cannabinoids.” https://www.ncsl.org/agriculture-and-rural-development/state-regulation-of-delta-8-thc-and-other-hemp-derived-cannabinoids